[go: up one dir, main page]

GT200900333A - Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6. - Google Patents

Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.

Info

Publication number
GT200900333A
GT200900333A GT200900333A GT200900333A GT200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A
Authority
GT
Guatemala
Prior art keywords
compounds
serotonine
modulation
receiver
kinoline
Prior art date
Application number
GT200900333A
Other languages
English (en)
Inventor
turner Sean
Braje Wilfried
Haupt Andreas
Lange Udo
Drescher Karla
Wicke Karsten
Unger Liliane
Mezler Mario
Wernet Wolfgang
Mayrer Mathias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900333A publication Critical patent/GT200900333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON NUEVOS COMPUESTOS DE QUINOLINA DE LA FÓRMULA I Y SALES DE LOS MISMOS. LOS COMPUESTOS TIENEN PROPIEDADES TERAPÉUTICAS VALIOSAS Y SON APROPIADOS, EN PARTICULAR, PARA TRATAR ENFERMEDADES QUE RESPONDEN A LA MODULACIÓN DEL RECEPTOR DE SEROTONINA 5-HT6. EN LA FÓRMULA I, R ES UNA PORCIÓN DE LA FÓRMULA EN DONDE * INDICA EL SITIO DE UNIÓN AL RADICAL QUINOLINILO Y EN DONDE A,B,X',Y,Q,R1,R2,R3,R4,R5,M,N,P,Q,RA, RB,X Y AR SON COMO SE DEFINEN EN LA REIVINDICACIÓN 1.
GT200900333A 2007-08-07 2009-12-29 Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6. GT200900333A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113962 2007-08-07

Publications (1)

Publication Number Publication Date
GT200900333A true GT200900333A (es) 2015-10-14

Family

ID=39809897

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900333A GT200900333A (es) 2007-08-07 2009-12-29 Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.

Country Status (22)

Country Link
US (2) US8293913B2 (es)
EP (1) EP2185555B1 (es)
JP (1) JP5501230B2 (es)
KR (1) KR20100039300A (es)
CN (1) CN101687866B (es)
AU (1) AU2008285652B2 (es)
BR (1) BRPI0812853A2 (es)
CA (1) CA2691529C (es)
CO (1) CO6251268A2 (es)
CR (1) CR11187A (es)
DO (1) DOP2009000291A (es)
EC (1) ECSP099831A (es)
ES (1) ES2574154T3 (es)
GT (1) GT200900333A (es)
IL (1) IL202706A (es)
MX (1) MX2009013956A (es)
NZ (1) NZ581986A (es)
RU (1) RU2483068C2 (es)
TW (1) TWI478919B (es)
UA (1) UA99626C2 (es)
WO (1) WO2009019286A1 (es)
ZA (1) ZA200909075B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
UA118201C2 (uk) 2013-11-26 2018-12-10 Ф. Хоффманн-Ля Рош Аг НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
KR102390045B1 (ko) * 2014-04-30 2022-04-22 카티바, 인크. 가스 쿠션 장비 및 기판 코팅 기술
PE20180479A1 (es) 2015-09-04 2018-03-07 Hoffmann La Roche Nuevos derivados de fenoximetilo
EP3353178B1 (en) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
JP6845230B2 (ja) * 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
EP3353176B1 (en) 2015-09-24 2022-01-19 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US10160744B2 (en) 2016-03-14 2018-12-25 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
EP3978497A4 (en) * 2019-05-30 2022-07-13 Shanghai Institute of Materia Medica, Chinese Academy of Sciences FUSED CYCLIC COMPOUND, METHOD FOR PREPARING IT AND ITS USE
MX2023015436A (es) * 2021-06-26 2024-02-21 Cedilla Therapeutics Inc Inhibidores de cdk2 y metodos de uso de los mismos.
EP4644396A1 (en) * 2022-12-28 2025-11-05 Visionpharma (Nantong) Co., Ltd Toll-like receptor inhibitor, and preparation therefor and application thereof
CN118359619A (zh) * 2023-01-18 2024-07-19 苏州旺山旺水生物医药股份有限公司 一种抗抑郁化合物的盐、其制备方法、包含其的药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861236B2 (de) * 1995-11-13 2006-08-16 Sanofi-Aventis Deutschland GmbH Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
DE10000739A1 (de) 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
PT1956004E (pt) * 2002-03-27 2012-08-31 Glaxo Group Ltd Derivados de quinolina e sua utilização como ligandos 5-ht6
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
JP2007510642A (ja) * 2003-11-03 2007-04-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害の治療のための新規ノルエピネフリン再取込み阻害薬
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
DE102004038268A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0425548D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
ATE465151T1 (de) 2005-07-27 2010-05-15 Hoffmann La Roche 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EP2185555B1 (en) 2016-03-16
ZA200909075B (en) 2013-03-27
JP5501230B2 (ja) 2014-05-21
RU2483068C2 (ru) 2013-05-27
BRPI0812853A2 (pt) 2014-12-23
DOP2009000291A (es) 2010-01-31
RU2010108282A (ru) 2011-09-20
CA2691529A1 (en) 2009-02-12
NZ581986A (en) 2012-02-24
AU2008285652B2 (en) 2013-09-05
UA99626C2 (ru) 2012-09-10
ECSP099831A (es) 2010-01-29
CN101687866A (zh) 2010-03-31
HK1143588A1 (zh) 2011-01-07
CO6251268A2 (es) 2011-02-21
US8440694B2 (en) 2013-05-14
WO2009019286A1 (en) 2009-02-12
TWI478919B (zh) 2015-04-01
MX2009013956A (es) 2010-04-30
US20130005703A1 (en) 2013-01-03
TW200914453A (en) 2009-04-01
IL202706A0 (en) 2010-06-30
IL202706A (en) 2014-08-31
CA2691529C (en) 2016-01-05
JP2010535739A (ja) 2010-11-25
EP2185555A1 (en) 2010-05-19
ES2574154T3 (es) 2016-06-15
US8293913B2 (en) 2012-10-23
US20100292271A1 (en) 2010-11-18
AU2008285652A1 (en) 2009-02-12
CR11187A (es) 2010-05-27
KR20100039300A (ko) 2010-04-15
CN101687866B (zh) 2014-06-04

Similar Documents

Publication Publication Date Title
GT200900333A (es) Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.
UY31402A1 (es) "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
BR112014026176A2 (pt) dipiridilaminas substituídas e usos das mesmas
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
ATE541832T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
UY31159A1 (es) Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos
AR061637A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ECSP088826A (es) Compuestos heterocíclicos apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5ht6
UY31326A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс